According to Novartis analysis on Sunday, the analysis showed that the use of Entresto tablets in the hospitalization of patients with heart problems was superior to Enalapril. These data were presented at the American Heart Association and published in The New England Journal of Medicine.
In the studied patients, the risk of heart failure was reduced by 46% when taking Entresto compared to enapril, they said. The results showed that newly hospitalized patients diagnosed with acute heart failure could be stabilized. In addition, Entresto's security and benefits have been confirmed.
In both Europe and the United States, Entresto is approved for certain heart problems in certain applications.